Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination

Rare cases of thrombosis with thrombocytopenia syndrome (TTS) have been reported after AZD1222. Anti-platelet factor-4 (PF4) antibodies were observed in patients following presentation of TTS, however it is unclear if AZD1222 was responsible for inducing production of anti-PF4. Paired samples (basel...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Taylor S., Kelly, Elizabeth J., Nylander, Sven, Bansal, Himanshu, Jepson, Brett M., Bhuyan, Prakash, Sobieszczyk, Magdalena E., Falsey, Ann R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103599/
https://www.ncbi.nlm.nih.gov/pubmed/35562373
http://dx.doi.org/10.1038/s41598-022-11623-9
_version_ 1784707594144710656
author Cohen, Taylor S.
Kelly, Elizabeth J.
Nylander, Sven
Bansal, Himanshu
Jepson, Brett M.
Bhuyan, Prakash
Sobieszczyk, Magdalena E.
Falsey, Ann R.
author_facet Cohen, Taylor S.
Kelly, Elizabeth J.
Nylander, Sven
Bansal, Himanshu
Jepson, Brett M.
Bhuyan, Prakash
Sobieszczyk, Magdalena E.
Falsey, Ann R.
author_sort Cohen, Taylor S.
collection PubMed
description Rare cases of thrombosis with thrombocytopenia syndrome (TTS) have been reported after AZD1222. Anti-platelet factor-4 (PF4) antibodies were observed in patients following presentation of TTS, however it is unclear if AZD1222 was responsible for inducing production of anti-PF4. Paired samples (baseline and day-15) from a phase 3 trial of AZD1222 vs placebo were analyzed for anti-PF4 levels; 19/1727 (1.1%, AZD1222) vs 7/857 (0.8%, placebo) participants were anti-PF4-IgG-negative at baseline but had moderate Day-15 levels (P = 0.676) and 0/35 and 1/20 (5.0%) had moderate levels at baseline but high Day-15 levels. These data indicate that AZD1222 does not induce a clinically relevant general increase in anti-PF4 IgG.
format Online
Article
Text
id pubmed-9103599
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91035992022-05-15 Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination Cohen, Taylor S. Kelly, Elizabeth J. Nylander, Sven Bansal, Himanshu Jepson, Brett M. Bhuyan, Prakash Sobieszczyk, Magdalena E. Falsey, Ann R. Sci Rep Article Rare cases of thrombosis with thrombocytopenia syndrome (TTS) have been reported after AZD1222. Anti-platelet factor-4 (PF4) antibodies were observed in patients following presentation of TTS, however it is unclear if AZD1222 was responsible for inducing production of anti-PF4. Paired samples (baseline and day-15) from a phase 3 trial of AZD1222 vs placebo were analyzed for anti-PF4 levels; 19/1727 (1.1%, AZD1222) vs 7/857 (0.8%, placebo) participants were anti-PF4-IgG-negative at baseline but had moderate Day-15 levels (P = 0.676) and 0/35 and 1/20 (5.0%) had moderate levels at baseline but high Day-15 levels. These data indicate that AZD1222 does not induce a clinically relevant general increase in anti-PF4 IgG. Nature Publishing Group UK 2022-05-13 /pmc/articles/PMC9103599/ /pubmed/35562373 http://dx.doi.org/10.1038/s41598-022-11623-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Cohen, Taylor S.
Kelly, Elizabeth J.
Nylander, Sven
Bansal, Himanshu
Jepson, Brett M.
Bhuyan, Prakash
Sobieszczyk, Magdalena E.
Falsey, Ann R.
Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
title Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
title_full Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
title_fullStr Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
title_full_unstemmed Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
title_short Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
title_sort serum levels of anti-pf4 igg after azd1222 (chadox1 ncov-19) vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103599/
https://www.ncbi.nlm.nih.gov/pubmed/35562373
http://dx.doi.org/10.1038/s41598-022-11623-9
work_keys_str_mv AT cohentaylors serumlevelsofantipf4iggafterazd1222chadox1ncov19vaccination
AT kellyelizabethj serumlevelsofantipf4iggafterazd1222chadox1ncov19vaccination
AT nylandersven serumlevelsofantipf4iggafterazd1222chadox1ncov19vaccination
AT bansalhimanshu serumlevelsofantipf4iggafterazd1222chadox1ncov19vaccination
AT jepsonbrettm serumlevelsofantipf4iggafterazd1222chadox1ncov19vaccination
AT bhuyanprakash serumlevelsofantipf4iggafterazd1222chadox1ncov19vaccination
AT sobieszczykmagdalenae serumlevelsofantipf4iggafterazd1222chadox1ncov19vaccination
AT falseyannr serumlevelsofantipf4iggafterazd1222chadox1ncov19vaccination

Ejemplares similares